Anti‐IL13 or anti‐IL4 agents vs placebo
Serious adverse events · people with asthma
Anti‐IL13 or anti‐IL4 agents showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
- Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents,… 2021 · Cochrane Headline outcomes onlyOR 0.91 [0.76, 1.09]22 studies · 7739 participantsModerate